Results 21 to 30 of about 82,161 (336)

The side effect profile of sirolimus and its relationship with some variables: A retrospective study of Iranian renal transplant patients

Journal of Research in Medical Sciences, 2023
Background: Sirolimus is a potent immunosuppressive in renal transplantation. However, its use is limited by some reported side effects. The objective of this study was to determine the side effect profile of sirolimus in renal transplant patients ...
Shahrzad Shahidi, Sahar Vahdat, Abdolamir Atatpour, Shirin Meshkinfar   +3 more
doaj   +1 more source

Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)

medRxiv, 2021
Introduction: β-thalassemia is caused by autosomal mutations in the β-globin gene, which induce the absence or low-level synthesis of β-globin in erythroid cells.
Cristina Zuccato, L. C. Cosenza, Matteo Zurlo, Jessica Gasparello, C. Papi, Elisabetta D’Aversa, Giulia Breveglieri, I. Lampronti, A. Finotti, M. Borgatti, C. Scapoli, Alice Stievano, M. Fortini, E. Ramazzotti, N. Marchetti, M. Prosdocimi, M. Gamberini, R. Gambari   +17 more
semanticscholar   +1 more source

Sirolimus in renal transplantation [PDF]

Nephrology Dialysis Transplantation, 2007
Acute rejection episodes are now as low as 5-20% in the first year after renal transplantation; however, graft half-life has remained almost unchanged in the last decade. This statistic is mainly attributable to the side effects of immunosuppression, with loss of allografts due to the chronic allograft nephropathy that is a consequence of calcineurin ...
Vedat Schwenger, Arianeb Mehrabi, Hamidreza Fonouni, Christian Morath, Martin Zeier, Jan Schmidt, Wolfgang Arns   +6 more
openaire   +3 more sources

Refractory Head and Neck Lymphatic Malformation in Infants Treated With Sirolimus: A Case Series

Frontiers in Oncology, 2021
Background Extensive and complex head and neck lymphatic malformations (LMs) are challenging to manage through traditional therapy. The purpose of this retrospective study was to assess the efficacy and safety of sirolimus in infants with refractory head
Changhua Wu, D. Song, Lei Guo, Liang-liang Wang   +3 more
semanticscholar   +1 more source

Effective low–dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach–Merritt phenomenon in young infants

British Journal of Clinical Pharmacology, 2021
Management of kaposiform haemangioendotheliomas (KHE) with Kasabach–Merritt phenomenon is challenging in young infants who are subjected to developmental pharmacokinetic changes.
Veroniek E. M. Harbers, Nathalie Salm, S. Pegge, C. Vleuten, B. Verhoeven, S. Vrancken, L. S. Schultze Kool, J. Fuijkschot, D. Loo   +8 more
semanticscholar   +1 more source

Oral antibiotic prophylaxis for infection in patients with vascular anomalies receiving sirolimus treatment: a multicenter retrospective study

Orphanet Journal of Rare Diseases, 2023
Objectives Patients with vascular anomalies (VAs) who receive oral sirolimus may be at high risk of infectious complications. Antibiotic prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMZ) has been advocated.
Tong Qiu, Yanan Li, Xue Gong, Jiangyuan Zhou, Kaiying Yang, Xuepeng Zhang, Zixin Zhang, Yuru Lan, Fan Hu, Qiang Peng, Yongbo Zhang, Feiteng Kong, Siyuan Chen, Yi Ji   +13 more
doaj   +1 more source

Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology

Pharmaceutics, 2021
Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as ...
Amelia-Naomi Sabo, Sarah Jannier, Guillaume Becker, Jean-Marc Lessinger, Natacha Entz-Werlé, Véronique Kemmel   +5 more
doaj   +1 more source

The Effects of Different Administration Regimens of Berberine Hydrochloride on the Pharmacokinetics of Sirolimus in Rats. [PDF]

Pharmacol Res Perspect
ABSTRACT Sirolimus is a third‐generation immunosuppressant with multiple efficacies, including antifungal, antitumor, and immunosuppressive properties. We conducted a pharmacokinetic study to determine the effect of berberine hydrochloride (BBR) on the pharmacokinetics of sirolimus in rats.
Yang Y, Zhang Y, Qu Y, Cui L.
europepmc   +2 more sources

Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

New England Journal of Medicine, 2003
BACKGROUND Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary revascularization.
J. Moses, M. Leon, J. Popma, P. Fitzgerald, D. Holmes, C. O'shaughnessy, R. Caputo, D. Kereiakes, David O. Williams, P. Teirstein, Judith Jaeger, R. Kuntz   +11 more
semanticscholar   +1 more source

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]

, 2016
PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly, DuBois, Steven G, Gustafson, W Clay, Hollinger, Fabienne, Karski, Erin E, Long-Boyle, Janel R, Matthay, Katherine K, Nasholm, Nicole M, Shiboski, Stephen, Vo, Kieuhoa T   +9 more
core   +1 more source